We previously reported the deubiquitinatingactivity of USP44 and subsequent EZH2 protein stabilization in prostate cancer cellsand suggested that targeting USP44 might be an efficient anticancer strategy forEZH2-dependent cancers irrespective of the enzymatic activity of EZH2 (Park et al., 2019). The gene discussed is EZH2; the disease is prostate carcinoma.